CeriBell's (CBLL) "Buy" Rating Reiterated at BTIG Research

Key Points

• BTIG Research reiterated its “Buy” rating on CeriBell and set a $30 price target, implying roughly 28% upside from the reported $23.43 share price. MarketBeat lists a consensus “Moderate Buy” rating with an average target of $24.40.
• CeriBell reported quarterly revenue of $28.10 million, exceeding estimates of $27.28 million, but its adjusted loss of $0.51 per share was wider than the expected $0.47 loss. Analysts expect a full-year loss of $1.96 per share.
• Insiders sold 391,901 shares worth approximately $8.54 million over the past three months, while insiders retain a 17.70% ownership stake. The stock was trading near its 52-week high, with a reported market capitalization of about $899 million.

CeriBell (NASDAQ:CBLL - Get Free Report)'s stock had its "buy" rating reissued by research analysts at BTIG Research in a research note issued to investors on Friday, Benzinga reports. They presently have a $30.00 target price on the stock. BTIG Research's price objective would suggest a potential upside of 28.04% from the stock's current price.

Other equities analysts also recently issued reports about the stock. Weiss Ratings downgraded shares of CeriBell from a "sell (d-)" rating to a "sell (e+)" rating in a report on Friday, August 28th. Raymond James Financial reaffirmed a "strong-buy" rating and issued a $29.00 price target on shares of CeriBell in a report on Thursday, September 3rd. Barclays upgraded shares of CeriBell to a "neutral" rating in a research report on Tuesday, August 18th. Finally, Canaccord Genuity Group lifted their price objective on CeriBell from $25.00 to $26.00 and gave the stock a "buy" rating in a research report on Tuesday, August 11th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $24.40.

CeriBell Stock Performance

NASDAQ CBLL opened at $23.43 on Friday. The business has a 50 day moving average price of $21.03 and a 200 day moving average price of $19.61. The company has a market capitalization of $899.24 million, a P/E ratio of -13.31 and a beta of 0.95. CeriBell has a 1-year low of $10.85 and a 1-year high of $25.33. The company has a debt-to-equity ratio of 0.16, a current ratio of 9.18 and a quick ratio of 8.79.

CeriBell (NASDAQ:CBLL - Get Free Report) last posted its earnings results on Monday, August 10th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.04). The firm had revenue of $28.10 million during the quarter, compared to analyst estimates of $27.28 million. CeriBell had a negative net margin of 64.73% and a negative return on equity of 44.85%. Sell-side analysts expect that CeriBell will post -1.96 EPS for the current fiscal year.

Insider Activity at CeriBell

In related news, CRO Joseph S. Manni sold 1,361 shares of the company's stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $24.02, for a total transaction of $32,691.22. Following the transaction, the executive owned 55,956 shares of the company's stock, valued at approximately $1,344,063.12. This represents a 2.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, VP David Foehr sold 9,255 shares of the firm's stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $24.25, for a total transaction of $224,433.75. Following the sale, the vice president owned 34,144 shares in the company, valued at approximately $827,992. This trade represents a 21.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 391,901 shares of company stock worth $8,542,455 over the last three months. Company insiders own 17.70% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Strs Ohio acquired a new stake in shares of CeriBell during the first quarter worth $27,000. Caitong International Asset Management Co. Ltd increased its stake in CeriBell by 3,971.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company's stock valued at $28,000 after purchasing an additional 1,231 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in CeriBell during the third quarter worth about $33,000. Tower Research Capital LLC TRC boosted its stake in CeriBell by 353.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company's stock worth $43,000 after buying an additional 1,801 shares during the last quarter. Finally, Legal & General Group Plc acquired a new stake in CeriBell in the 2nd quarter worth about $53,000.

About CeriBell

CeriBell Corp NASDAQ: CBLL is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell's solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company's product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.